Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Key Insights
The FDA has granted Rare Pediatric Disease designation to Atossa Therapeutics' (Z)-Endoxifen for treating Duchenne Muscular Dystrophy (search), expanding the drug's development beyond oncology.
This regulatory milestone may qualify Atossa for a Priority Review Voucher upon approval, which has recently sold for $100-160 million.
(Z)-Endoxifen offers a differentiated mechanism as a SERM/D that doesn't target specific exon defects, potentially providing broader treatment access for DMD patients.
Atossa Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy (search), marking a significant regulatory milestone that expands the drug candidate's potential beyond oncology into rare pediatric neuromuscular diseases.
The RPD designation is reserved for drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher, which can be used to obtain priority review for future applications or sold to another sponsor. In the last 18-24 months, disclosed PRV sales have ranged from $100-160 million.
Regulatory and Commercial Implications
"This designation is an important regulatory milestone for Atossa, and we believe a strong validation of the science supporting the potential of (Z)-Endoxifen as a treatment for Duchenne Muscular Dystrophy (search)," said Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer. "DMD is one of the most devastating childhood diseases. Families urgently need better options beyond steroids and gene-targeted approaches."
The FDA may not award any new rare pediatric disease PRVs unless the application is for a drug designated as a rare pediatric disease not later than December 20, 2024, and approved under the program not later than September 30, 2026. The House has passed the Mikaela Naylon "Give Kids a Chance Act" to extend voucher-award authority to 2029, with retroactive effect, and the bill is now pending Senate action.
Differentiated Therapeutic Approach
Janet Rea, MSPH, Senior Vice President of Research and Development at Atossa, emphasized the drug's unique mechanism of action. "We are very encouraged by emerging preclinical data and by (Z)-Endoxifen's potential to be a differentiated mechanism as a potent SERM/D, and look forward to our planned advancement of this program to the clinic for boys living with DMD."
Unlike more recent therapeutic approaches, (Z)-Endoxifen does not target specific exon defects, thus potentially offering a broader and more accessible treatment approach for the DMD patient population. Rea noted her previous experience securing IND clearance for what is now the DMD treatment Exondys 51® (eteplirsen).
Disease Background and Unmet Need
Duchenne Muscular Dystrophy (search) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin (search) gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy. DMD is uniformly fatal, often in early adulthood, and despite recent therapeutic advances, there remains a substantial unmet medical need for safe, effective, and accessible treatments.
About (Z)-Endoxifen
(Z)-Endoxifen is a potent Selective Estrogen Receptor (search) Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition.
Quay noted that while oncology remains the company's core focus, this milestone highlights (Z)-Endoxifen's potential as a platform therapy in both cancer and rare diseases, opening the door to potential non-dilutive value creation through the Rare Pediatric Disease program.
Atossa's (Z)-Endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide. The drug is not currently approved for any indication.